Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.
Adimab was founded in 2007 by Errik Anderson, K. Dane Wittrup, Tillman Gerngross.
Adimab's investment strategy appears to focus on early to mid-stage companies within the biotechnology, pharmaceutical, and therapeutics sectors, specifically those that align with health care, science, and engineering industries. The firm's investments are geographically concentrated in the United States, with a preference for entities located in Massachusetts. Adimab does not typically take a lead role in the funding rounds it participates in. The company's approach suggests a strategic interest in innovative firms that are likely to contribute to the expansion of biologics pipelines and complement Adimab's antibody discovery and optimization platform. Organizations that could attract Adimab's attention for future investments are likely to be U.S.-based biotech firms with a focus on novel therapeutic development, potentially those working on antibody technologies or other areas that can synergize with Adimab's platform and expertise.
1282 health care and life sciences companies are in the directory, 165 of them in the same 101-250 employee range and 75 based in East Coast.
Adimab may be growing as indicated by the recent announcement of a substantial expansion of its research campus. This expansion suggests an increase in operational capacity and potentially a broadening of its research and development activities. Such a move typically reflects a positive trajectory in a company's growth, as it often requires significant investment and implies confidence in future business prospects. The expansion of a research campus in the biotechnology industry, where Adimab operates, is a strong indicator of growth, as it enables the company to enhance its capabilities in antibody discovery and optimization.
“Accelerate antibody therapeutics with Adimab’s yeast-based antibody discovery and engineering platform built for developability and clinical success.” adimab.com
Adimab is a biotechnology company based in East Coast, with 101-250 employees, founded in 2007. Its founders are Errik Anderson, K. Dane Wittrup and Tillman Gerngross and it has raised $45.5 million over 8 rounds.
101-250 employees · aveooncology.com
101-250 employees · abivax.com
51-100 employees · 1859.ai
51-100 employees · acrivon.com
51-100 employees · 4basebio.com
501-1,000 employees · adaptivebiotech.com
11-50 employees · advancells.com
11-50 employees · a-biodesign.com
11-50 employees · alxoncology.com
11-50 employees · aardvarktherapeutics.com
Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.